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Abstract 
Objectives were to identit~¢ the PKC isoforms in cultured muscle cells, to examine roles of Ca2+-dependent proteinases (calpains) in 
processing of various muscle PKC isozymes and to obtain a mechanistic description of the processing of PKCs by examining the 
temporal relationships between phorbol ester-dependent translocation of muscle PKCs and calpains between cytosolic and membrane 
compartments. Using six isoform (a ,  /3, 3', 3, ~, ,~ )-specific polyclonal antibodies, PKC a, ~ and s r were detected in rat skeletal muscle 
and in L8 myoblasts and myetubes. PKC a and ,~ were primarily localized in the cytosolic fraction of L8 myotubes whereas PKC ~ was 
more abundant in the membrane fraction. Phorbol ester (TPA) caused rapid depletion of myotube PKC a and PKC 8 isoforms from the 
cytosolic compartment and rapid appearance of these isoforms in the membrane fraction. However, long-term exposure of myotubes to 
TPA eventually caused down.-regulation f PKCs in the membrane compartment. Down-regulation of PKCs in the membrane fraction was 
partially blocked by calpain inhibitor II. However, the rapid TPA-dependent cytosolic depletion of PKCs was unaffected by calpain 
inhibitor. This suggests that calpains may be responsible for membrane-associated down-regulation of PKCs but not for cytosolic 
depletion. In the final study we assessed the effects of phorbol ester on compartmentation of m-calpain with PKCs in muscle cells. Like 
the PKCs, TPA caused rapid association of m-calpain with the membrane fraction followed by down-regulation. This demonstrates that 
phorbol esters cause translocation of both PKCs and calpains to membranes where processing of PKCs may occur via the limited 
proteolysis exerted by calpains. 
Keywords: Protein kinase C; Calpain; Phorbol ester; Muscle cell 
1. Introduction 
Protein kinase C (PKC), a serine/threonine kinase, is 
thought o play important roles in the control of a wide 
range of cellular processe~;, which include secretion, con- 
traction, membrane receptor function, cell differentiation 
and tumor promotion [1,2]. Protein kinase C is activated by 
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Ca 2+ and diacylglycerol, which are generated from the 
receptor-mediated hydrolysis of membrane phospholipids 
(PL). Molecular cloning studies revealed that the PKC 
gene family contains at least ten different isozymes that 
can be divided into two or three major groups [3-6]. The 
first group consists of four conventional PKCs (cPKC): a, 
/31, /31I and 7. The cPKC isoforms are activated by Ca 2÷, 
phosphatidylserine and diacylglycerol or phorbol ester 
(PE). The second group consists of four novel PKCs 
(nPKC): 8, e, r/(L), and 0 which are activated by phos- 
phatidylserine and diacylglycerol r PE but not by Ca 2+. A 
third group consists of two atypical PKCs (aPKC): ~" and 
A. aPKCs require only phosphatidylserine for activation. 
Because the individual isozymes have different cofactor 
requirements, ubcellular distribution and substrate speci- 
ficity, the profile of PKC isoforms expressed in a particu- 
lar tissue is likely an important determinant of that tissue's 
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response to an endocrine challenge. Differential tissue 
distribution of PKC isoforms have been reported by many 
authors [7-10]. 
Calpains are Ca2+-activated neutral proteinases ex- 
pressed as house-keeping proteinases. Two isoforms exist 
in most tissues (/z- and m-calpain) and house-keeping 
functions include cytoskeletal protein turnover, receptor 
processing and processing and/or activation of protein 
kinase C isoforms [3,11-13]. A membrane-activation 
model for the calpains was proposed by Mellgren [14] and 
Suzuki et al. [15] in which calpains exist normally as 
inactive cytosolic pro-enzymes but, in response to an 
increase in cell Ca 2÷, calpains translocate to the cell 
membrane where they undergo autolysis. Hence, mem- 
brane-bound proteins are believed to be ideal calpain 
substrates. Once at the membrane, calpain activities are 
modulated by phospholipids [15]. 
In skeletal muscle, PKCs and calpains play key roles in 
differentiation and growth processes. PKC has been impli- 
cated in hypertrophy [16], contraction-induced muscle 
metabolism [17], glucose transport [18], myoblast differen- 
tiation [19,20] and proliferation [21]. We have determined 
that TPA increased muscle protein degradation 5 in my- 
otubes. However, very little is known about the PKC 
isoforms in muscle, their regulation and individual func- 
tions. Although calpains may play a key role in control of 
myofibrillar protein degradation [11], their roles in the 
processing and activation of muscle PKCs have not been 
studied. In this study, we characterized the isoenzymes of 
PKC, their subcellular distribution in skeletal muscle and 
their differential down-regulation by phorbol ester (TPA). 
Furthermore, we investigated the role that calpains play in 
the TPA-dependent down-regulation of muscle PKCs. 
These studies demonstrate that phorbol esters not only 
induce translocation of the PKCs to membranes but also 
coordinate translocation of the protease responsible for 
their processing to the same compartment. 
bond-C Super and Hybond-ECL nitrocellulose membranes, 
horseradish peroxidase (HRP) conjugated onkey anti-rab- 
bit IgG and ECL Western blotting analysis system were 
from Amersham (Arlington Heights, IL). Alkaline phos- 
phatase (AP) conjugated goat anti-rabbit (GAR) IgG, alka- 
line phosphatase conjugate substrate kit, SDS-PAGE low 
molecular weight standard, and Bio-Rad protein assay dye 
reagent were from Bio-Rad (Richmond, CA). Culture 
dishes were from Coming (Coming, New York). Ca 2÷- 
channel blockers, nifedipine and ryanodine, were obtained 
from Calbiochem Corporation (San Diego, CA). 
2.2. Cell culture 
L8 rat skeletal muscle cells were obtained from Ameri- 
can Type Culture Collection (Rockville, MD). Cells, stored 
in liquid nitrogen, were thawed and maintained by re- 
peated sub-culturing atlow density on 10-cm culture dishes. 
Cells were grown in Dulbecco's-modified Eagle's medium 
(DMEM) supplemented with 10% FBS, 100 units of peni- 
cillin/ml, 100 /zg of streptomycin/ml, 44 mM NaHCO 3, 
110 /xg of sodium pyruvate/ml in a humidified atmo- 
sphere of 5% CO 2 and 95% air at 37 ° C. The medium was 
changed every 2 days. Cells (2.5 × 10 4 cells/cm 2) were 
grown in the presence of 10% FBS until they reached 
confluency. At this point the medium was replaced by 
DMEM containing 2% HS to induce differentiation. Ap- 
proximately 3 days later, when myotube formation was 
observed, the cells were treated with 10 /zM cytosine 
arabinoside for 48 h to remove any remaining dividing 
myoblasts. Microscopic examination was used to monitor 
differentiation. All studies were conducted at times during 
which 90-95% of all nuclei were myotubular. After the 
appropriate incubation time, cells were harvested for West- 
ern blotting analysis. 
2.3. Preparation of m-calpain antibody 
2. Materials and methods 
2.1. Materials 
Fetal bovine (FBS) and horse (HS) sera were from 
Hyclone (Logan, UT). Dulbecco's modified Eagle's 
medium, penicillin/streptomycin solution, trypsin solu- 
tion, and affinity-purified anti-PKC isozyme-specific (a,  
/3, y, 6, E, and ~') antibodies were from GIBCO (Grand 
Island, NY). Calpain inhibitor II and leupeptin were from 
Boehringer Mannheim (Indianapolis, IN). Cytosine-/3-D- 
arabinofuranoside (Ara-C), 12-O-tetradecanoyl phorbol- 
13-acetate (TPA), dimethyl sulfoxide and bovine serum 
albumin (BSA) were from Sigma (St. Louis, MO). Hy- 
An antipeptidic antibody against the amino-terminal 
18-mer segment of rat m-calpain was developed using a 
synthetic peptide, AGIAAKLAKDREAAEGLGC, conju- 
gated to keyhole limpet hemocyanin and affinity-purified 
as previously described [22]. This antibody was designed 
to specifically recognize native (pre-autolysis 80 kDa iso- 
form) m-calpain [22]. The antibody binds only to 80 kDa 
m-calpain and not to other calpain (/z-) isoforms and is 
sensitive nough to detect its antigen in crude cell lysates 
[22]. This antibody has also been used in previous tudies 
to monitor the autolysis of m-calpain in intact cells with 
concomitant proteolysis of calpain substrate [22]. 
2.4. Preparation of tissue and cell extracts for Western 
blotting 
s Hong and Forsberg, unpublished observations 
The following method was used for extraction of total 
PKC from tissues and cultured cells for preliminary studies 
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on PKC isoforms in mus.cle tissues and brain. Male rats 
were killed by cervical dislocation and the brain and 
muscle were immediately removed and homogenized in 
ice-cold Buffer A (20 mM Tris-HC1 [pH 7.5], 0.25 M 
sucrose, 50 mM /3-mercaptoethanol, 1 mM PMSF, 200 
/zg/ml  of leupeptin, 5 mM EDTA, 2 mM EGTA, 10 mM 
benzamidine, 0.2% Triton X-100) using a Polytron. L8 
myotubes and myoblasts were prepared by washing cells 
with ice-cold PBS, after which they were scraped from 
their plates in Buffer A and homogenized in this buffer by 
sonication. Homogenates were kept at 4 ° C for 1 h then 
centrifuged at 100000 X g for 30 min at 4 ° C. The super- 
natant was either used immediately or frozen at -80°C  
for SDS-PAGE. Protein concentration was determined by 
the method of Bradford [23]. 
The following method was used for isolation of mem- 
brane and cytosolic fractions from cultured L8 myotubes 
[24]. Myotubes were recovered from culture plates (by 
washing with ice-cold PI~S followed by scraping) follow- 
ing various treatments with either phorbol ester or calpain 
inhibitor and homogenized in Buffer B (Buffer A lacking 
Triton X-100) using a Dounce homogenizer. Cells were 
centrifuged at 100000× g for 20 min at 4°C. Super- 
natants were used as the cytosolic fraction. To obtain 
membrane fractions, L8 cell pellets were washed and 
extracted with Buffer B containing 1% Triton X-100. After 
30 min incubation at 4 ° C, the samples were centrifuged at 
12 000 x g for 20 min yielding the solubilized membrane 
fraction. Protein concentrations of individual samples were 
determined by the method of Bradford [23]. Details of 
individual studies are presented in text and legends to 
figures. 
2.5. Western blot analysis 
Protein samples were subjected to 10% SDS-PAGE 
according to the method of Laemmli [25]. The separated 
proteins were electrophoretically transferred to a nitro- 
cellulose membrane (Hybond-C Super or Hybond-ECL) at 
4 ° C overnight using a Bio-Rad Transfer Blot apparatus 
(30 mAmp) by the method of Towbin et al. [26]. Non- 
specific sites were blocked by incubation of nitrocellulose 
membranes with 2% BSA in TBST (50 mM Tris-HC1, pH 
7.5, 0.15 M NaC1, 0.05% Tween-20) for 1 h at room 
temperature. Anti-PKC antibodies or m-calpain pAb were 
incubated with the membranes for 2 h at room tempera- 
ture. The antibody dilutions were as follows: a,  1:333; fl, 
1:333; Y, 1:333; 6, 1:200; e, 1:333; ~', 1:200; and m- 
calpain 1:500. After three washes (15 min) with TBST, 
secondary antibody (AP-conjugated goat anti-rabbit IgG, at 
1:3000 dilution; or HRP-conjugated onkey anti-rabbit 
IgG, at 1:2000) was added and incubated for 1 h at room 
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Fig. 1. Western blot analysis of protein kinase C isozymes (or, fl, and 3') in muscle cytosol. Protein samples (100 /xg) from rat L8 myoblasts (lane 1), L8 
myotubes (lane 2), rat skeletal muscle (lane 3) and rat brain (100 /zg for a and 6, 50 /zg for fl; lane 4) were subjected toWestern blot analysis as 
described inSection 2. Positions of molecular weight markers are shown on the left: (from the top) 97.4, 66.2, 42.7, 31.0 and 21.5 kDa. Arrows indicate 
positions of PKC isozymes. 
48 
1 2 
D.-h. Hong et al. / Biochimica et Biophysica Acta 1267 (1995) 45-54 
A B 
3 4 1 2 3 4 1 2 3 4 
PKC-6 PKC-e PKC-~" 
Fig. 2. Western blot analysis of protein kinase C isozymes ((5 and e; panel A, and ~; panel B) in muscle cytosol. Protein samples from rat L8 myoblasts 
(lane 1), L8 myotubes (lane 2), rat skeletal muscle (lane 3) and rat brain (lane 4) were subjected to Western blot analysis as described in Section 2. For 
PKC t~, e and r 150, 100 and 150/xg of protein were electrophoresed, respectively. Positions of molecular weight markers are shown on the left: (from 
the top) 97.4, 66.2, 42.7 and 31.0 kDa. Blots on panel A were processed using the alkaline phosphatase d tection system. Panel B was developed using the 
more sensitive ECL detection system. Arrows indicate positions of PKC isozymes. 
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Fig. 3. Effects of calpain inhibitor II on TPA-induced down-regulation of PKC-o~ in L8 myotubes. L8 myotubes were treated with 300 ng/ml  TPA 
(phorbol ester) in the absence or presence of 100 nM calpain inhibitor II (CI; N-acetyl-leucyl-leucyl-methioninal) for 0, 6 or 24 h. Cytosolic (Cy; lanes 
1-5) and membrane (M; lanes 6-10) fractions were prepared for Western blot analysis. Positions of molecular weight markers are shown on the left: (from 
the top) 97.4, 66.2, 42.7, and 31.0 kDa. Arrows indicate positions of PKC isozymes. 250 /xg of protein were loaded per lane. 
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Fig. 4. Effects of calpain inhibitor II on TPA-induced own-regulation f PKC-6 in L8 myotubes. L8 myotubes were treated with 300 ng/ml  TPA in the 
absence or presence of 100 nM ralpain inhibitor II (CI; N-acetyl-leucyl-leucyl-methioninal) for 0, 6 or 24 h. Cytosolic (Cy; lanes 1-5) and membrane (M; 
lanes 6-10) fractions were prep~tred for Western blot analysis. Positions of molecular weight markers are shown on the left: (from the top) 97.4, 66.2, 42.7, 
and 31.0 kDa. Arrows indicate positions of PKC isozymes. 150 p,g of protein were loaded per lane. 
temperature. Following this incubation, the membrane was 
washed (15 min) three times with TBST. Specific binding 
of anti-PKC or anti-m-ca[pain antibodies was detected by 
either the alkaline pbosphatase detection kit (Bio-Rad) or 
the ECL detection system (Amersham). Where necessary, 
blots were scanned using a Hewlett-Packard Scan-Jet II 
CX scanning densitometer using NIH Image Software 
(Version 1.54) and a Power Macintosh (Model 7100/66). 
CI + 
TPA TPA 
Ih] 0 6 24 6 24 
PKC-~_  ~ ~ ~ / ~  
2.6. Studies with Ca 2 +-channel blockers. 
Effects of phorbol ester on translocation of calpains in 
the presence and absence of Ca 2+ channel blockers was 
investigated. Blockers included nifedipine (1-10 jxM) and 
ryanodine (5-50/zM). Nifedipine was dissolved in ethanol 
then added to culture media at either 5 or 10 min prior to 
additions of phorbol ester. Ryanodine was dissolved in 
C I  
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Fig. 5. Effects of calpain inhibitor II on TPA-induced own-regulation f PKC-~" in L8 myotubes. L8 myotubes were treated with 300 ng/ml  TPA in the 
absence or presence of 100 nM calpain inhibitor II (CI; N-acetyl-leucyl-leucyl-methioninal) for 0, 6 or 24 h. Cytosolic (Cy; lanes 1-5) and membrane (M; 
lanes 6-10) fractions were prepared for Western blot analysis. Positions of molecular weight markers are shown on the left: (from the top) 97.4, 66.2 and 
42.7 kDa. Arrows indicate positions of PKC isozymes. 150 /zg of protein were loaded per lane. 
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Fig. 6. Effects of TPA (300 ng/ml)  on cytosolic and membrane-bound m-calpain (panel A), PKC tz (panel B) and PKC 6 (panel C). TPA was added to 
cultures of myotubes for 0 min (lanes 1 and 8), 10 rain (lanes 2 and 9), 30 min (lanes 3 and 10), 1 h (lanes 4 and 11), 3 h (lanes 5 and 12), 6 h (lanes 6 and 
13) or 24 h (lanes 7 and 14) after which concentrations of m-calpain and PKCs were determined by Western blot analysis. Lanes 1-7 correspond to the 
cytosolic fraction and lanes 8-14 correspond to the membrane fraction. Western blotting was completed as outlined in Section 2. 100 p.g of protein were 
loaded per lane. Molecular weight markers of 66 kDa and 97 kDa are indicated. In this and following figures, myotubes were maintained in 2% HS and 
SDS-PAGE was performed on 7.5% SDS-PAGE gels. Scanning densitometry of data presented in the lower panel. For comparative purposes, values are 
expressed as a proportion of initial (unstimulated) antigens associated with the membrane fraction. 
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sterile water prior to being added to culture media at either 
5 or 10 rain prior to additions of phorbol ester. Effects of 
TPA on m-calpain compartmentation were examined fol- 
lowing 2 min of exposure to TPA. 
m-Calpain-~ 
Membrane 
1 2 3 4 5 
3. Results 
3.1. PKC isoforms in muscle 
We used affinity-purified isozyme-specific polyclonal 
antibodies to detect PKC ,:~, /3, y, 6, • and ~ isoforms in 
extracts from rat L8 myoblasts and L8 myotubes, skeletal 
muscle and brain. Extracts from rat brain were used as a 
positive control (Figs. 1 and 2). We detected PKC a (Fig. 
1), PKC 6 (Fig. 2A) and PKC ~" (Fig. 2B) in all muscle 
samples. However, PKC ~" concentration i adult muscle 
was very low. PKCs /3, .y and • were not detectable in 
the muscle samples. The apparent molecular weight of 
both PKC a and PKC ~ was 80 kDa. The PKC ~" 
isozyme-specific antibody recognized a predominant 70 
kDa protein in rat brain plus two uncharacterized proteins 
of 85 and 52 kDa. In myotubes, myoblasts and adult 
muscle, the PKC ~" antibody recognized a 70 kDa protein 
(PKC ~') plus a larger protein (> 100 kDa). PKC ~" 
concentration i  L8 myotubes and myoblasts and brain 
was much higher than that detected in adult skeletal mus- 
cle. 
3.2. Subcellular distribution and down-regulation ofPKC 
isoforms by TPA 
Next we examined the subcellular distribution of three 
PKC isoforms in L8 myotubes and their response to TPA 
(Figs. 3, 4 and 5). TPA was administered either for 6 or 24 
h. Phorbol ester reduced concentrations of myotube PKC 
a and PKC 6 (Figs. 3 and 4) in both cytosolic and 
membrane fractions. PKC ~', in both cytosolic and mem- 
brane fractions, was unaffe.cted by TPA (Fig. 5). Although 
PKC a was depleted in the cytosolic fraction, trace 
amounts of PKC a were detected in the membrane frac- 
tion of L8 myotubes following both 6 and 24 h exposure to 
TPA (Fig. 3). Six and 24 h of TPA treatment eliminated 
PKC 6 from the cytosolic compartment; however, trace 
quantities of this isozyme also remained associated with 
the membrane fraction following both 6 and 24 h exposure 
to TPA (Fig. 4). The TPA-dependent down-regulation of
PKC a and PKC 8 in the membrane fraction was partially 
blocked by calpain inhibitor II (Figs. 3 and 4). However, 
this inhibitor did not block the TPA-dependent transloca- 
tion of the ce and ~ isozymes from the cytosolic fraction 
to the membrane fraction. PKC ~', which does not bind 
TPA [3], was neither translocated nor down-regulated by 
TPA treatment and was umesponsive to calpain inhibitor II 
treatment (Fig. 5). 
Because calpains may process and activate PKCs, we 
Fig. 7. Effects of calcium channel blockers on TPA-dependent transloca- 
tion of m-calpain to the membrane fraction of L8 myotubes. The treat- 
ments included no pre-treatment (lane 1), TPA (300 ng/ml) for 2 min 
(lane 2), pre-treatment with 50 ~M ryanodine for 10 min followed by 
addition of TPA for 2 min (lane 3), pre-treatment with nifedipine (10 
/xM) for 10 min followed by TPA (lane 4) and pre-treatment with both 
ryanodine and nifedipine followed by TPA (lane 5). Following TPA 
treatment, he membrane fraction was recovered and membrane-associ- 
ated m-calpain concentration was determined by Western blotting. 
hypothesized that phorbol esters may also bring about 
translocation of calpains to membranes to facilitate this 
event. Hence, we investigated the temporal effects of TPA 
on the compartmentation f the 80 kDa m-calpain large 
subunit, PKC a and PKC 8 in myotubes (Fig. 6A-C). 
Treatment of myotubes with TPA did not affect cytosolic 
m-calpain concentration but caused a several-fold accumu- 
lation of membrane-associated m-calpain (Fig. 6A). The 
effect of TPA on membrane m-calpain was maximal fol- 
lowing 10 min of exposure after which membrane m- 
calpain concentration declined slowly with time. Ten rain 
of TPA treatment were sufficient o deplete cytosolic PKC 
a and PKC 6 (Fig. 6B) and this depletion was maintained 
for the 24-h duration of the study. Translocation of PKCs 
to the membrane fraction was complete within 10 min. 
Following 1 h of TPA treatment, membrane PKC concen- 
trations began to decline. Of interest, m-calpain was cleared 
from the membrane fraction at a rate slightly faster than 
PKC a clearance (Fig. 6A). Phorbol ester-dependent 
down-regulation of membrane PKC 6, however, lagged 
behind the down-regulation of membrane PKC a and 
m-calpain. 
To determine whether the TPA-dependent translocation 
of m-calpain to membranes was dependent upon sarco- 
plasmic- or voltage-dependent Ca2+-channels, we tested 
ability of TPA to cause translocation of the 80 kDa 
m-calpain large subunit in the presence and absence of two 
Ca 2 + channels blockers (nifedipine and ryanodine, respec- 
tively; Fig. 7). Again, phorbol ester caused translocation of
m-calpain to the membrane fraction. However, nifedipine 
and ryanodine, added alone or in combination, did not 
interfere with TPA-dependent translocation of m-calpain. 
4. Discussion 
In this study, we demonstrated the presence of Ca :+- 
and PL-dependent PKC a, Ca2+-independent but PL-de- 
pendent PKC 6 and Ca 2 +- and PL-independent PKC ~" in 
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L8 myoblasts, L8 myotubes and rat adult muscle. PKCs a, 
and ( were present in both undifferentiated and differen- 
tiated L8 muscle cells although the PKC ~" concentration, 
in adult muscle, was very low. These findings confirm 
other studies which reported PKC c~ [27] and PKC 6 [28] 
in muscle. The presence of PKC /3 in muscle was reported 
by Hanaina et al. [29] and Nakano et al. [30]. However, we 
were unable to detect PKC /3 in myoblasts, myotubes or 
rat muscle even when loading much higher quantities of 
protein on gels. Perhaps only a small amount of PKC /3 is 
expressed in skeletal muscle. The quantitative immuno- 
blotting by Yoshida et al. [31] indicated that PKC /3 in 
muscle was very low compared other tissues. We detected 
a 70 kDa single band with the PKC ~" antibody in muscle 
cells, whereas a 70- and 85 kDa doublet were detected in 
brain. These results are consistent with previous findings 
where multiple immunoreactive PKC ~'s were detected in 
other tissues [18,32,33]. The lower molecular weight bands 
found in blots of PKC a and PKC 6 (Figs. 3 and 4) may 
represent non-specific binding of the pAbs because phor- 
bol ester had no effect on the cellular distributions or 
concentrations of these proteins. Alternatively, the low 
MW bands may be processed components of PKC which 
possess the epitope but are not responsive to phorbol ester. 
A feature of the regulation of PL-dependent PKCs is 
their translocation to membranes following interaction with 
phorbol ester [3,10,34]. We studied this in detail in muscle 
cells using TPA: a diacylglycerol analog. The membrane 
fraction in this study consisted principally of sarcolemma 
but also included other membranous fractions including 
mitochondrial and sarcoplasmic reticulum. PKC a and 
PKC 6 were translocated to membranes by TPA; how- 
ever, the PKC ~ isozyme did not translocate or down-reg- 
ulate in response to TPA. In contrast, Borner et al. [34] 
reported the translocation of rat fibroblast PKC ~" by 
phorbol ester. However, most studies indicate that PKC ~" 
is resistant o TPA-induced translocation or down-regu- 
lation [35-37]. 
Our results revealed two distinct TPA-dependent pro- 
cesses involved in control of muscle PKCs: one of which 
was calpain-independent, thesecond of which we suggest 
is calpain-dependent. Treatment of muscle cells with phor- 
bol ester first caused the rapid translocation of PKC c~ and 
PKC 6 from the cytosol to membranes. Two lines of 
evidence suggest hat the disappearance of the a and 6 
isoforms from the cytosol was not the result of proteolysis. 
First, disappearance of PKCs from this pool was accompa- 
nied by concomitant appearance of immunoreactive pro- 
teins of the same molecular weights in the membrane 
fraction. Second, inhibition of calpains, the enzymes which 
appear to be responsible for processing of PKCs, by 
addition of calpain inhibitor II did not prevent he disap- 
pearance of PKCs from the cytosolic compartment. 
The second effect of phorbol ester was to effect down- 
regulation of membrane PKCs. Two lines of evidence 
support the theory that calpains mediated this phe- 
nomenon. First, calpain inhibitor reduced the ability of 
TPA to deplete membrane PKCs. Second, native (80 kDa) 
m-calpain translocated to the membrane fraction in re- 
sponse to TPA and was eliminated from the membrane 
fraction in advance of the down-regulation f PKCs a and 
6. Because our calpain antibody recognized only the intact 
80 kDa pro-m-calpain, the loss of calpain immunoreactiv- 
ity from the membrane prior to the loss of the PKCs may 
indicate the necessity for m-calpain to be proteolyticaily 
processed and activated prior to the processing and down- 
regulation of membrane-associated PKCs. The absence of 
immunoreactive PKC fragments in the cytosolic and mem- 
brane fractions following extended treatment with TPA 
suggests that the proteolyzed PKC is rapidly degraded. 
The limitation of these studies is that calpain inhibitor II 
is not a fully selective inhibitor. It also inhibits the multi- 
catalytic proteinase (MCP: proteasome) [38] and other 
cysteine proteinases including the lysosomal cysteine pro- 
teases. However, in this study the concentration of calpain 
inhibitor II used was less than that which is required to 
inhibit MCP [38]. Hence, it is very unlikely that calpain 
inhibitor II reduced the TPA-dependent down-regulation f
PKC by inhibiting the MCP. Further, lysosomes typically 
do not degrade membrane-associated proteins, whereas 
calpains do. Our observations that a portion of m-calpain 
translocated to the membrane fraction and the considerable 
evidence that calpains degrade membrane-associated pro- 
teins including PKCs [3,39,40] causes us to suggest hat 
calpain inhibitor II exerted its actions via the calpains. 
The reason why cytosolic m-calpain concentration did 
not change despite the rapid appearance of immuno- 
reactive m-calpain at the membrane is not clear. In other 
studies (data not shown) we verified that 6 and 24 h of 
TPA treatment did not change L8 myotube total m-calpain 
subunit concentration. Earlier studies [41] have determined 
that a TPA-responsive element (TRE) resides in the human 
m-calpain promoter and that TPA increases m-calpain 
transcription. Based on this it is possible that TPA rapidly 
increases ynthesis of m-calpain in muscle cells in order to 
maintain fixed levels of this protease in the cytosol. Alter- 
natively, there may simply exist an abundance of cytosolic 
m-calpain in unstimulated myotubes and the portion of 
m-calpain which is translocated to membranes in response 
to TPA represents only a small portion of this total. If true, 
this would leave the majority of m-calpain in an inactive 
cytosolic pool available for use for other housekeeping 
functions. 
The mechanism by which phorbol esters induce down- 
regulation of membrane PKC is not fully understood. 
Savart et al. [13] suggested that TPA binding to the 
regulatory domains of PKCs (C1 region) may cause a 
conformational change in PKC, increasing its affinity for 
calpain and allowing its proteolysis at physiological con- 
centrations of Ca 2+. A recent circular dichroism study 
showed that binding of TPA to PKC caused marked 
changes in secondary structure [42]. This may explain why 
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PKC ~', which lacks TPA binding sites, is not down-regu- 
lated by TPA. 
Earlier studies by Pontremoli et al. [43] have shown that 
phorbol esters induce translocation of calpain to neutrophil 
membranes. We found a similar phenomenon i  cultured 
muscle cells and propose, that a coordinated transfer of 
PKCs with their processing protease to membranes may 
represent a mechanism for PKC activation and/or  degra- 
dation in muscle. However, the mechanism by which TPA 
caused translocation of m-calpain to the membrane frac- 
tion is not clear. The 'Mellgren/Suzuki model' proposes 
that an increase in cell Ca 2+ concentration brings about 
calpain translocation to n~embranes [14,15]. Activation of 
PKCs can bring about chzmges in cell Ca 2+ concentration 
[19,42,44]. Hence, the ability of TPA to cause calpain 
translocation could be direct (i.e., TPA may bind to calpain 
and thereby induce m-c~.lpain translocation) or indirect 
(i.e., TPA may increase cytosolic Ca2+). To test the 
second possibility, we examined the ability of TPA to 
induce m-calpain translocation following treatment of my- 
otubes with nifedipine and ryanodine administered alone 
or in combination. Nifedipine is a selective blocker of 
cellular voltage-operated Ca2+-channels. Ryanodine is an 
inhibitor of Ca 2+ efflux from the sarcoplasmic reticulum. 
However, neither of these inhibitors interfered with the 
ability of TPA to cause translocation of m-calpain to 
membranes. Hence, the mechanism by which TPA induces 
translocation of m-calpain to membranes i unresolved. 
Based on these and others' results, we present the 
model shown in Fig. 8 fi~r PKC a and 6 activation in 
muscle. This model builds upon an earlier model we 
Fig. 8. Model for the relationship between PKC c~ and 6 and calpain in 
muscle cells. Binding of ligand I:o its receptor (R) causes hydrolysis of 
phosphotidyl-inositol-4,5-bisphosphate (PIP 2) by membrane phospho- 
lipase C (PLC). This generates two second messengers: diacylglycerol 
(DAG) and inositol triphosphate (IP3). IP 3 causes release of Ca 2+ from 
sarcoplasmic reticulum (SR). Phorbol ester (PE) or diacylglycerol (DAG) 
cause translocation f PKC ot and 6 and m-calpain to the membrane 
fraction. There, the newly-released Ca2+ regulates membrane-bound 
calpain activities which cause processing ofPKC a and 6. This process- 
ing either activates PKC (by generating a PKC metabolite (PKM) which 
is constitutively active) or represents the first step in PKC degradation 
and inactivation. Phosphotidylserine (PS) and the newly-released Ca 2+ 
also regulate PKC translocation a d activity. This figure was adapted 
from our earlier work [45]. 
proposed for corpus luteum [45]. Briefly stated, activation 
of phospholipase C by ligand releases two second messen- 
gers: IP 3 and diacylglycerol. While IP 3 releases intra- 
cellular Ca 2÷, diacylglycerol acts directly upon PKCs c~ 
and 6 and induces their translocation to the membrane 
fraction. Simultaneously, DAG, either directly or indi- 
rectly, causes the translocation of m-calpain to membranes. 
There, m-calpain, in the presence of sufficient Ca 2+, un- 
dergoes autolysis and may process PKC. This may either 
activate PKC (i.e., generating a constitutively-active PKM) 
or may represent he preliminary step in muscle PKC 
degradation. The unique elements of this model which 
were identified in this study include the identification of 
PKC isoforms in muscle, their translocation with m-calpain 
to membranes in response to phorbol ester and the process- 
ing of muscle PKC a and 6 in membrane fractions by 
calpain. 
In conclusion, muscle cells contain at least three PKC 
isoforms (a ,  y and ~r ). Their presence is not dependent on 
differentiation. These isoforms permit three different signal 
transduction pathways to exist in muscle: Ca 2+- and PL- 
dependent (PKC ix), Ca2+-independent but PL-dependent 
(PKC 6) and Ca 2-- and PL-independent (PKC () .  This 
diversity explains the wide range of functions in muscle 
that have been attributed to PKC. As in other cells, the a 
and 6 isoforms, but not the ~" isoform, are translocated 
and down-regulated by TPA and are substrates for mem- 
brane-bound calpain. Of particular interest, translocation of 
PKCs with their putative processing proteinase is coordi- 
nated by phorbol ester. These observations point to a 
highly coordinately movement of signal transduction ma- 
chinery to the membrane upon myotube stimulation. It is 
likely that these responses underlie many aspects of mus- 
cle cell physiology and it is now critical that we identify 
which hormones rely upon these transduction phenomena 
to coordinate their cellular events and to identify the 
cytosolic and nuclear events which follow PKC isoform 
activation and down-regulation. 
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